Jpmorgan Chase & CO Alvotech Transaction History
Jpmorgan Chase & CO
- $1.51 Trillion
- Q3 2025
A detailed history of Jpmorgan Chase & CO transactions in Alvotech stock. As of the latest transaction made, Jpmorgan Chase & CO holds 24,455 shares of ALVO stock, worth $134,257. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,455
Previous 24,455
-0.0%
Holding current value
$134,257
Previous $200,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ALVO
# of Institutions
65Shares Held
15.1MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA4.35MShares$23.9 Million0.0% of portfolio
-
Bracebridge Capital, LLC2.71MShares$14.9 Million12.58% of portfolio
-
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca1.56MShares$8.58 Million0.33% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.45MShares$7.98 Million0.0% of portfolio
-
Littlejohn & CO LLC1.32MShares$7.24 Million12.0% of portfolio
About Alvotech
- Ticker ALVO
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 248,650,000
- Market Cap $1.37B
- Description
- Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...